Literature DB >> 11690621

The shifting biology of prions.

M Glatzel1, A Aguzzi.   

Abstract

Transmissible spongiform encephalopathies (TSEs), or prion diseases, are rare fatal neurodegenerative diseases of humans and animals. Although some TSEs, like scrapie in sheep, have been known to exist for centuries, bovine spongiform encephalopathy (BSE) was recognized only 15 years ago. New variant Creutzfeldt-Jakob disease (nvCJD) of humans is probably caused by consumption of BSE-infected materials. The nature of the infectious agent is not fully elucidated, but substantial evidence suggests that it is devoid of nucleic acids and consists at least in part of an abnormal form of a host protein termed PrP(C). Despite their rarity, prion diseases have become an important topic in public health and basic research because of the connection between nvCJD and BSE and also because of the unusual biological attributes of the infectious agent.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11690621     DOI: 10.1016/s0165-0173(01)00100-x

Source DB:  PubMed          Journal:  Brain Res Brain Res Rev


  3 in total

1.  No reactivation of JCV and CMV infections in the temporal cortex and cerebellum of sporadic Creutzfeldt-Jakob disease patients.

Authors:  Judith Löffler; Susanne Krasemann; Inga Zerr; Jakob Matschke; Markus Glatzel
Journal:  Am J Neurodegener Dis       Date:  2014-12-05

2.  Prion protein polymorphisms associated with reduced CWD susceptibility limit peripheral PrPCWD deposition in orally infected white-tailed deer.

Authors:  Alicia Otero; Camilo Duque Velásquez; Chad Johnson; Allen Herbst; Rosa Bolea; Juan José Badiola; Judd Aiken; Debbie McKenzie
Journal:  BMC Vet Res       Date:  2019-02-04       Impact factor: 2.741

3.  A common BACE1 polymorphism is a risk factor for sporadic Creutzfeldt-Jakob disease.

Authors:  Olga Calero; María J Bullido; Jordi Clarimón; Ana Frank-García; Pablo Martínez-Martín; Alberto Lleó; María Jesús Rey; Isabel Sastre; Alberto Rábano; Jesús de Pedro-Cuesta; Isidro Ferrer; Miguel Calero
Journal:  PLoS One       Date:  2012-08-30       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.